APOE and Alzheimer disease: The discovery of apoE Christchurch and the beneficial effect of the hybrid apoE2 + Christchurch variant in AD mouse models represent major breakthroughs in the field and could accelerate the development of clinical trials to assess the efficacy of AAV-mediated apoE therapy in AD [236].